The first RSV vaccine for older adults is now available in some US pharmacies. GSK’s Arexvy (palivizumab) was approved by the FDA in May 2023 and is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older.
